Lanckriet Heikki 4

What Happened

• Heikki Lanckriet, a director of Biofrontera Inc. (BFRI), was granted 20,000 derivative securities on March 4, 2026. The transaction is reported as an award/acquisition (code A) with a reported price of $0.00 and total reported value $0. This was a grant of derivative awards (e.g., options or other equity-based awards), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-03-06 (timely filing).
• Amount: 20,000 derivative awards; reported price per unit: $0.00; reported value: $0.
• Vesting: Footnote indicates the award vests in 12 equal monthly installments beginning April 4, 2026.
• Other awards: Footnote notes options with different terms are not included in this reporting, so other outstanding awards may exist.
• Shares/units owned following the reported transaction: Not specified in the provided filing.

Context

• This is a grant of derivative securities (an award) rather than a purchase or sale. The awards will vest monthly over a year, meaning the recipient earns the award over time rather than receiving immediately tradable shares.
• Such grants are typically part of compensation or retention programs; the filing does not state any immediate sale or exercise.